Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness (Journal of Psychopharmacology 21, 2, DOI: 10.1177/0269881107065738);Venlafaxine-mirtazapine combination in the treatment of persistent depressive illness

Journal of Psychopharmacology

Volumn 21, Issue 2, 2007, Pages 161-164

  Hannan, Noel ^a   Hamzah, Zaf ^a   Akinpeloye, Henry Omoniyi ^a   Meagher, David ^a  

^a UNIVERSITY HOSPITAL LIMERICK   (Ireland)

Author keywords

Combination treatment; Depression; Mirtazapine; Venlafaxine

Indexed keywords

DULOXETINE; MIRTAZAPINE; NEUROLEPTIC AGENT; VENLAFAXINE;

ADULT; AGED; AGITATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG DOSE ESCALATION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MALE; MONOTHERAPY; NAUSEA; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SEDATION; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; WEIGHT GAIN;

EID: 33847155589     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108096188     Document Type: Erratum

References (16)

1. Aydemir O, Taskin E O, Deveci A (2005) Mirtazapine augmentation in treatment-resistant major depressive disorder: an open-label, six week trial. European Neuropsychopharmacology 15 (suppl 3). 401 - 402
2. Benazzi F (2005) Hemorrhages during escitalopram-venlafaxine-mirtazapine combination treatment of depression. Canadian J Psychiatry 50 (3). 184-184
3. Blier P, Tremblay P M, Ward H E, Hebert C, Bergeron R (2005) Antidepressant drug combination from treatment initiation to improve therapeutic response in major depression. European Neuropsycho-pharmacology 15 (suppl 3). 449 - 450
4. Carpenter L L, Yasmin S, Price L H (2002). A double-blind, placebo-controlled study of antidepressant augmentation with Mirtazapine. Biol Psychiatry 51: 183 - 188
5. Carpenter L L, Jocic Z, Hall J M, Rasmussen S A, Price L H (1999) Mirtazapine augmentation in the treatment of refractory depression. J Clin Psychiatry 60: 45 - 49
6. Dimellis (2002) Serotonin syndrome produced by a combination of venlafaxine and mirtazapine. World J Biol Psychiatry 3: 167-167
7. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Bethesda, MD: US Department of Health Education and Welfare
8. Houlihan D J (2004). Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine. Ann Pharmacother 38 (3). 411 - 413
9. Meagher D, Moran M (2003) Sub-optimal prescribing in an adult community mental health service: prevalence and determinants. Psychiatric Bulletin 27: 266 - 271
10. Moran M, Raju B, Saunders J, Meagher D (2006) Achieving evidencebased prescribing practices in an adult community mental health service. Psychiatric Bulletin 30: 51 - 55
11. National Institute of Clinical Excellence (2004) Depression: management of depression in primary and secondary care. Clinical Guideline 23, December
12. Raju B, Meagher D (2005) Patient-controlled benzodiazepine dose reduction in a community mental health service. Irish J Psychol Med 22: 42 - 45
13. Rush A J, Fava M, Wisniewski S R, Lavori P W, Trivedi M H, Sackeim H A, Thase M E, Nierenberg A A, Quitkin F M, Kashner T M, Kupfer D J, Rosenbaum J F, Alpert J, Stewart J W, McGrath P J, Biggs M M, Shores-Wilson K, Lebowitz B D, Ritz L, Niederehe G, STAR*D Investigators Group (2004) Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25 (1). 119 - 142
14. Stahl S M (2000) Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 2nd edn. Cambridge University Press, Cambridge
15. Taylor D, Paton C, Kerwin R (2005) The South London and Maudsley NHS Trust 2005-2006 Prescribing Guidelines, 8th edn. Taylor and Francis, Oxford
16. World Health Organization (1993) The ICD-10 Classification of Mental and Behavioural Disorders. WHO, Geneva